Toleranzia AB

0EH

Company Profile

  • Business description

    Toleranzia AB is a Swedish biotechnology company. It develops drugs that harness the power of the immune system to treat autoimmune orphan diseases. The company uses its tolerance technology for drug development, which is based on the identification of disease-specific proteins that are developed into biological drugs, specific to each autoimmune disease. Its drug development pipeline includes TOL2, which is being developed for the treatment of autoimmune orphan disease myasthenia gravis, and TOL3, being developed for another indication in autoimmune orphan diseases, ANCA vasculitis.

  • Contact

    Arvid Wallgrens backe 20
    8th floor
    Gothenburg413 46
    SWE

    T: +46 763199898

    https://www.toleranzia.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    10

Stocks News & Analysis

stocks

The 10 best US dividend stocks

These are the top dividend-paying stocks to buy in 2025.
stocks

ASX listed tariff play

Trump’s focus on US steel production may benefit this firm.
stocks

Ask the analyst: How reliant are Guzman shares on international growth?

A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,006.80116.001.30%
CAC 407,822.670.670.01%
DAX 4024,289.5181.42-0.33%
Dow JONES (US)44,342.19142.30-0.32%
FTSE 1008,992.1219.480.22%
HKSE24,825.66326.711.33%
NASDAQ20,895.6510.010.05%
Nikkei 22539,819.1182.08-0.21%
NZX 50 Index12,880.4025.01-0.19%
S&P 5006,296.790.57-0.01%
S&P/ASX 2008,757.20118.201.37%
SSE Composite Index3,534.4817.660.50%

Market Movers